fda compounding semaglutide warning november 2025 Compounded Semaglutide: Legal & Safe 2025

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

24.38

★★★★☆4.8 (126)

We're warning consumers of concerns with compounded medications containing semaglutide: https://www.fda .gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing- semaglutide-marketed-type-2-diabetes-or-weight-loss

29.18

★★★★★4.9 (98)

The FDA recently published updates clarifying policies for compounding drug manufacturers producing GLP-1 medications post drug shortage. In this post, Dr. Brian LaMar explains what those updated guidelines mean, why Parkview Weight

21.95

★★★★★5.0 (157)

November 2025 Drug Safety: Recalls for Compounded Semaglutide, Generic Synthroid; Safety updates for Lamictal, Kineret, Miebo eye drops, Zoladex; Microneedling Injuries, more

24.25

★★★★★4.7 (84)

FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products

28.01

★★★★★4.9 (203)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

26.51

★★★★★5.0 (176)

WRTV Investigates has learned the FDA sent 30 warning letters to telehealth companies for illegally marketing compounded GLP-1s. MORE

25.14

★★★★★4.8 (132)